In light of the concept of the mutant selection window, i.e., the range between the MIC and the mutant prevention concentration (MPC), MPC-related pharmacokinetic indices should be more predictive of bacterial resistance than the respective MIC-related indices. However, experimental evidence of this hypothesis remains limited and contradictory. To examine the predictive power of the ratios of the area under the curve (AUC 24 ) to the MPC and the MIC, the selection of ciprofloxacin-resistant mutants of four Escherichia coli strains with different MPC/MIC ratios was studied. Each organism was exposed to twice-daily ciprofloxacin for 3 days at AUC 24 /MIC ratios that provide peak antibiotic concentrations close to the MIC, between the MIC and the MPC, and above the MPC. Resistant E. coli was intensively enriched at AUC 24 T he concept of the mutant selection window (MSW), i.e., the range between the MIC and the mutant prevention concentration (MPC) (1), has contributed to an understanding of why antibiotic-resistant mutants are enriched in some but not all treatments. In light of this hypothesis, MPC-related pharmacokinetic indices should be more predictive of bacterial resistance than the respective MIC-related indices. However, the advantages of the former over the latter indices have been reported in only a few in vitro studies with ciprofloxacin-exposed (2) and levofloxacin-exposed(3) Staphylococcus aureus and with ciprofloxacin-exposed Escherichia coli (4). On the other hand, the predictive potentials of the MPC-and MIC-related indices were shown to be similar in an in vivo study of Streptococcus pneumoniae-infected rabbits treated with gatifloxacin using a human-like dosing regimen (5) and in an in vitro study with marbofloxacin-and enrofloxacin-exposed E. coli (6). In our in vitro study with S. aureus exposed to daptomycin and vancomycin, the ratio of the 24-h area under the concentration-time curve (AUC 24 ) to the MPC was less predictive of bacterial resistance than the AUC 24 /MIC ratio (7).
T
he concept of the mutant selection window (MSW), i.e., the range between the MIC and the mutant prevention concentration (MPC) (1) , has contributed to an understanding of why antibiotic-resistant mutants are enriched in some but not all treatments. In light of this hypothesis, MPC-related pharmacokinetic indices should be more predictive of bacterial resistance than the respective MIC-related indices. However, the advantages of the former over the latter indices have been reported in only a few in vitro studies with ciprofloxacin-exposed (2) and levofloxacin-exposed(3) Staphylococcus aureus and with ciprofloxacin-exposed Escherichia coli (4) . On the other hand, the predictive potentials of the MPC-and MIC-related indices were shown to be similar in an in vivo study of Streptococcus pneumoniae-infected rabbits treated with gatifloxacin using a human-like dosing regimen (5) and in an in vitro study with marbofloxacin-and enrofloxacin-exposed E. coli (6) . In our in vitro study with S. aureus exposed to daptomycin and vancomycin, the ratio of the 24-h area under the concentration-time curve (AUC 24 ) to the MPC was less predictive of bacterial resistance than the AUC 24 /MIC ratio (7) .
To further examine the predictive power of AUC 24 /MPC and AUC 24 /MIC, the selection of ciprofloxacin-resistant mutants of four E. coli strains at various MPC/MIC ratios was studied over a wide range of simulated AUC 24 /MICs.
MATERIALS AND METHODS
Antimicrobial agents, bacterial strains, and susceptibility testing. Ciprofloxacin powder was purchased from AppliChem Biochemica Chemical Synthesis Services, Darmstadt, Germany.
E. coli ATCC 25922, E. coli clinical isolates 4300 and 4454, and E. coli laboratory strain mutator GM2995 (ES1578) (8) were selected for the study. The MICs were determined prior to and after 3-day simulated treatments with ciprofloxacin. Susceptibility testing was performed at least in duplicate by broth microdilution techniques at 24 h postexposure with organisms grown in Ca 2ϩ -and Mg 2ϩ -supplemented Mueller-Hinton broth (MHB) at an inoculum size of 10 6 CFU/ml. The MICs of ciprofloxacin were 0.008 g/ml with E. coli strains ATCC 25922, 4300, and 4454 and 0.016 g/ml with E. coli strain GM2995.
The MPCs were determined as described elsewhere (2) . Briefly, the tested microorganisms were cultured in MHB and incubated for 24 h. The suspension was then centrifuged (4,000 ϫ g for 10 min) and resuspended in MHB to yield a concentration of ϳ10 10 CFU/ml. A series of agar plates containing known ciprofloxacin concentrations were then inoculated with ϳ10
10 CFU of E. coli. The inoculated plates were incubated for 48 h at 37°C and screened visually for growth. To estimate the MPC, logarithms of bacterial numbers were plotted against antibiotic concentrations. The MPC was taken as the point at which the plot intersected the lower limit of detection (log CFU/ml ϭ 1).
In vitro dynamic model and simulated pharmacokinetic profiles. A previously described dynamic model (9) was used in the study. Briefly, the model consisted of two connected flasks, one containing fresh BBL Trypticase soy broth (TSB) and the other with a magnetic stirrer, the central unit, with the same broth containing a bacterial culture plus antibiotic. Peristaltic pumps circulated fresh nutrient medium to the flasks and from the central 100-ml unit at a flow rate of 17.3 ml/h.
The system was filled with sterile TSB and placed in an incubator at 37°C. The central unit was inoculated with an 18-h culture of E. coli. After 2 h of incubation the resulting exponentially growing cultures reached ϳ10 8 CFU/ml, and ciprofloxacin solutions were injected into the central unit at 12-h intervals. The duration of the experiments was defined in each case as the time after the last dose when ciprofloxacin-exposed bacteria reached numbers observed at the beginning of the experiment (Ն10 8 CFU/ml).
A series of monoexponential profiles that mimic twice-daily dosing of ciprofloxacin with a half-life (t 1/2 ) of 4 h was simulated for 3 consecutive days. The simulated t 1/2 represented weighted means of values reported for humans: 3.2 to 5.0 h (10). The profiles were designed to provide 24-h ratios of area under the curve (AUC 24 ) to the MIC ratios from 9 to 15 h to 2,880 h (E. coli strains ATCC 25922 and GM2995) and from 15 to 720 h (E. coli strains 4300 and 4454).
Ciprofloxacin concentrations in the central unit of the model were determined by an HPLC assay. Isocratic separation was performed at 30°C on a Luna C18(2) column (250 by 4.6 mm; particle size, 5 m; Phenomenex, Torrance, CA). The injection volume was 10 l. The mobile phase consisted of a 3.5-g/liter solution of phosphoric acid, previously adjusted to pH 3.0 with triethylamine-acetonitrile-methanol (volume ratio, 860:111:29) at a flow rate of 1.2 ml/min (Gilson 305; Gilson S.A.S., Villiers-le-Bel, France). The column effluent was monitored with the fluorescence detector (Waters 2475; Waters Associates, Milford, MA) at 278 nm (excitation) and 450 nm (emission). The calibration plot was linear (r 2 Ն 0.99) over the concentration range of 0.04 to 0.5 g/ml. The within-run relative standard deviations (n ϭ 5) was 1.4%. The lower limit of accurate detection was 0.04 g/ml. The determined concentrations of ciprofloxacin were in concordance with the target values without systematic differences over the entire observation period. The estimated half-life of ciprofloxacin was close to the target value (4.3 Ϯ 0.2 h).
Quantitation of the antimicrobial effect and susceptibility changes. In each experiment, bacterium-containing medium from the central unit of the model was sampled to determine bacterial concentrations throughout the observation period. Samples (100 l) were serially diluted as appropriate and spirally plated onto TSB agar plates using Easy Spiral Pro (Interscience, St. Nom, France). Colonies were counted by an automated colony counter Interscience Scan 1200 (Interscience, St. Nom, France). The lower limit of counting was 200 CFU/ml (equivalent to 20 colonies per plate). To reveal resistant mutants, each sample was serially diluted if necessary and plated manually onto agar plates containing 2ϫ, 4ϫ, 8ϫ, and 16ϫ the MIC of ciprofloxacin. The lower limit of detection was 10 CFU/ml (equivalent to at least one colony per plate). To reveal changes in susceptibility of ciprofloxacin-exposed bacterial cultures, the MICs were reassessed after antibiotic exposures.
Based on time-kill data, the intensity of the antimicrobial effect, i.e., the area between the control growth and time-kill curves (I E ) (9, 11) from time zero to the time after the last antibiotic dose at which the number of antibiotic-exposed bacteria reached 10 8 CFU/ml, was determined. To delineate AUC 24 /MIC and AUC 24 /MPC relationships with resistance, areas under the bacterial concentration-time curves (AUBCs, i.e., the AUBKC [12] ) with mutants (AUBCMs [2] ) were determined for subpopulations resistant to 2ϫ, 4ϫ, 8ϫ, and 16ϫ the MIC of antibiotic from the beginning of treatment to 72 h corrected for the areas under the lower limit of detection over the same time interval.
Relationships of the antimicrobial effect to AUC 24 /MIC. The I E -log AUC 24 /MIC curve was fitted by the sigmoid function:
where 
where Y is AUBC M , Y 0 is the minimal value of Y, x is log (AUC 24 /MIC), log (AUC 24 /MPC) or T ϾMPC , and a and b are parameters. Mechanisms of resistance. The nucleotide sequences of the quinoloneresistance determining regions (QRDRs) of gyrA and parC genes were determined for both parental and mutated strains by PCR and sequencing as previously described (13) .
Bacterial genomic DNA was isolated using the InstaGene matrix kit (Bio-Rad Laboratories, Inc., Hercules, CA). Amplified fragments were purified by exonuclease I/shrimp alkaline phosphatase (ExoSAP-IT) treatment (GE Healthcare, Ltd., Buckinghamshire, United Kingdom) and were sequenced on both strands using the same primers as in the PCR with the BigDye Terminator v3.1 cycle sequencing kit and ABI Prism 310 genetic analyzer (Applied Biosystems, Foster City, CA). The sequences obtained were compared to those previously reported for gyrA (GenBank accession no. NC_004431, region 2623646.0.2626273) and parC genes (GenBank accession no. NC_004431, region 3593045.0.3595303).
RESULTS
In determining the MPCs, the numbers of surviving E. coli colonies decreased systematically with increasing ciprofloxacin concentrations in the plates (Fig. 1) . With E. coli strains ATCC 25922, 4454, and GM2995, a rapid decay of CFU counts was observed, and the estimated MPCs were of the same order: 0.11, 0.25, and 0.5 g/ml, respectively. Unlike these three organisms, E. coli 4300 exhibited a biphasic pattern of the log CFU-concentration curve with a rapid decay in number of colonies at ciprofloxacin concen- tration of 0 to 0.016 g/ml, followed by a plateau at concentrations from 0.5 to 4 g/ml, and then again a rapid decline in CFU at higher antibiotic concentrations. The MPC of ciprofloxacin determined using the last three points on the CFU-concentration curve was estimated at 15 g/ml.
Simulated concentrations and the time courses of ciprofloxacin-exposed E. coli grown on antibiotic-free (0ϫ the MIC) and antibiotic-containing (4ϫ and 16ϫ the MIC) media are shown in Fig. 2 . As seen in the figure (second row), small and transient reductions, if any, in the number of susceptible cells were observed at the lower AUC 24 /MIC ratios (9 to 15 h). More noticeable reductions (2.5-to 5-fold) in bacterial numbers, followed by regrowth 6 h after the start of experiments, were seen at an AUC 24 /MIC ratio of 180 h. The most pronounced reductions (3.5-to 6-fold) in bacterial numbers and the latest regrowth toward the end of simulated treatments were seen at the highest AUC 24 /MIC ratio of 720 h. At a given AUC 24 /MIC ratio, similar time-kill curves were observed with all ciprofloxacin-exposed organisms.
The respective resistance data are shown in the last two rows of Fig. 2 . At the minimal AUC 24 /MIC ratios (9 to 15 h) E. coli mutants resistant to 4ϫ the MIC of ciprofloxacin were enriched on the second (E. coli GM2995), third (E. coli 4454), or fourth day after the start of simulated treatment (E. coli 4300 and ATCC 25922), although the maximal numbers of mutants were 2 to 6 orders lower than those of susceptible cells (third row of Fig. 2 ). At the higher AUC 24 /MIC ratio (180 h), the amplification of resistant mutants of all four organisms started earlier, on the second day, and maximal mutant counts approached the maximal values seen with susceptible cells. At the highest AUC 24 /MIC ratio (720 h), resistant mutants were not enriched during the treatments, although they were enriched after discontinuing treatment. The same patterns were established with the most resistant mutant (fourth row of Fig. 2 ) and with intermediate mutants, resistant to 2ϫ and 8ϫ the MIC of ciprofloxacin (data not shown). The enrichment of resistant E. coli was accompanied by a concomitant loss in the susceptibility of ciprofloxacin-exposed organisms. At am AUC 24 /MIC of 180 h, the mean MIC elevation for the four studied organisms was more pronounced (a 25-fold increase in the MIC) than at 9 to 15 h and 720 h (10-and 8-fold increases in the MIC, respectively).
The results of PCR amplification and sequencing of the QRDRs of gyrA and parC genes are shown in the Table 1 . In all of the mutants the genetic analysis revealed the presence of single nucleotide substitutions in the gyrA QRDR sequences corresponding to amino acid changes, Ser83Leu (E. coli ATCC 25922 and E. coli 4300), Asp87Tyr (E. coli GM2995), and Asp87Gly (E. coli 4454). None of the isolates had changes in parC. Since none of the strains, including E. coli 4300, had double mutations in gyrA or additional mutations in parC, the MPC ratio of 15 g/ml that describes the second-step mutations, is not applicable in our case. This circumstance allows us to make a rough approximation of the MPC for E. coli strain 4300 for the first-step mutants assuming that the first two points of the curve exhibiting the number of colonies that arose on ciprofloxacin-containing agar plates belong to the first-step mutants (dotted line in the upper plot in Fig. 1 ). The respective MPC was estimated at 0.1 g/ml, and this value was used in the subsequent analysis.
Plots of the AUC 24 /MIC and AUC 24 /MPC relationships with AUBC M are represented by similar bell-shaped curves (upper panel of Fig. 3 ). With each organism, the AUBC M increased with an increase in the AUC 24 /MIC or AUC 24 /MPC, reaching a maximum and then, at higher AUC 24 /MICs or AUC 24 /MPCs, the AUBC M decreased to zero. The enrichment of resistant mutants led to a loss in susceptibility of ciprofloxacin-exposed E. coli. Maximal loss was observed at AUC 24 /MICs (or AUC 24 /MPCs) corresponding to the top of the bell curves: at AUC 24 /MIC ratios of 180 and 360 h, the MIC elevations seen with the studied organisms averaged 25-fold; at smaller (30 and 60 h) and larger (720 h) AUC 24 /MICs, the elevations were Ͻ10-fold.
As seen in the left portion of the figure, both ascending and descending branches of the bells seen with all four organisms were virtually superimposed, although the maximal AUBC M observed with E. coli GM2995 was less than with the other three strains at comparable AUC 24 /MICs. Unlike the AUC 24 /MIC, the AUC 24 / MPC curves of the AUBC M s determined with the different organisms were more stratified (right portion of Fig. 3 ). This resulted in more variable estimates of the anti-mutant AUC 24 /MPCs (from 25 to 100 h, a 4-fold difference) compared to the corresponding estimates of the AUC 24 /MIC ratio (from 720 to 1,440 h, a 2-fold difference). The mean values of the anti-mutant AUC 24 /MPC and AUC 24 /MIC ratios were estimated to be 58 Ϯ 35 and 1,080 Ϯ 416 h, respectively. For the same reason, a Gaussian-like function fits the AUBC M -AUC 24 /MPC combined data set worse than the AUBC M -AUC 24 /MIC set (bottom panel of Fig. 3 ): r 2 ϭ 0.69 versus r 2 ϭ 0.86. Both the AUC 24 /MPC and the AUC 24 /MIC resistance relationships were more strain specific than the AUC 24 /MIC relationship with the ciprofloxacin antimicrobial effect on susceptible E. coli: using combined data on the four studied organisms, a strong correlation was established between I E and AUC 24 /MIC (r 2 ϭ 0.96; Fig. 4 ).
DISCUSSION
This study was designed to search for optimal predictors of the development of bacterial resistance and showed similar patterns of the AUC 24 /MPC and AUC 24 /MIC relationships with the selection of resistant mutants of ciprofloxacin-exposed E. coli. These relationships were described by bell-shaped curves for all organisms: resistant mutants were intensively enriched at AUC 24 /MPC from 1 to 10 h and at AUC 24 /MIC from 60 to 360 h but not at lower or higher AUC 24 /MPC and AUC 24 /MIC ratios. However, AUBC M versus AUC 24 /MPC curves were more specific for each organism than the respective AUBC M versus AUC 24 /MIC curves. As seen in the upper panel of Fig. 3 , the former curves were more stratified than the latter curves. As a result, a Gaussian-like function fits AUBC M versus AUC 24 /MPC data that were combined for the four organisms worse than the AUBC M -AUC 24 /MIC data (bottom panel of Fig. 3 ): r 2 ϭ 0.69 versus r 2 ϭ 0.86. A similar but less pronounced difference would be seen if only points on the descending branch of the bell (i.e., the branch that has defining value for prediction of the anti-mutant antibiotic concentration) were considered (Fig. 5) . Although the AUC 24 / MPC and AUC 24 /MIC relationships with the AUBC M were similar, the enrichment of resistant E. coli correlated better with AUC 24 /MIC than with AUC 24 /MPC or the time above the MPC (T ϾMPC ): r 2 ϭ 0.81 versus r 2 ϭ 0.74 and 0.71, respectively. Not surprisingly, the anti-mutant AUC 24 /MPC ratios vary from strain to strain in a broader range than the respective AUC 24 /MIC ratios (a 4-fold versus a 2-fold difference). Even less clear AUC 24 /MPC relationships with resistance compared to AUC 24 /MIC relationships were observed previously with daptomycin-and vancomycin-exposed S. aureus (7) . In two other studies, E. coli exposed to marbofloxacin and enrofloxacin in an in vitro model (6) and pneumococcal pneumonia in rabbits treated with gatifloxacin (5), both AUC 24 /MPC and AUC 24 /MIC exhibited similar bell-shaped relationships with resistance. In fact, the advantages of AUC 24 / MPC over AUC 24 /MIC were clearly proven in three in vitro studies: ciprofloxacin-exposed E. coli (4) and ciprofloxacin-exposed (2) and levofloxacin-exposed (3) S. aureus. The reasons for these discrepancies remain unclear. Obviously, they could result from different experimental design and data interpretation, the choice of bacterial strains, the range of simulated AUC 24 /MIC and/or AUC 24 /MPC ratios, the indices reflecting resistance development, etc. For example, the choice of bacterial strains exhibiting an insufficient range of the MPC/MIC ratio could prevent accurate discrimination between the MPC-and MIC-related indices as predictors of bacterial resistance. On the other hand, the use of an insufficient range of simulated AUC 24 / MIC and/or AUC 24 /MPC could lead to an unbalanced range of the target effects (the prevalence of resistance manifestations or the lack thereof). However, our analysis of the cited studies does not confirm these concerns. Indeed, in studies showing the advantages of MPC-related indices over MIC-related indices (2-4), the MPC/MIC range was of the same order (4-to 8-fold differences in MPC/MIC) as in studies that do not show such advantages (5-7; the present study): 3-to 8-fold differences in MPC/MIC. Also, the AUC 24 /MIC ratios simulated (or achieved) in the latter four studies varied over at least 48-fold (the present study), 16-to 33-fold (7), 8-fold (5) and 6-to 7-fold (6) compared to 3-to 5-fold (2), 8-fold (3), and at least 16-fold (4). As for the determination of resistance, similar measures (the ratio of the postexposure MIC to the pre-exposure MIC [3, 6] , population analysis data [4, 5; the present study], or both measures [2, 7] ) were used both in studies showing the advantages of AUC 24 /MPC over AUC 24 /MIC and in studies that did not support this point.
The anti-mutant AUC 24 /MIC and AUC 24 /MPC ratios predicted in our study (1,080 and 58 h, respectively) are at least 3-fold higher than those previously reported with ciprofloxacin-exposed E. coli (4): 45 to 364 h and 11 to 23 h, respectively. This difference could result from the shorter observation period used in the referenced study (24 h versus 72 h in the present study): insufficient simulated treatment and/or observation duration could lead to an underestimation of the anti-mutant antibiotic concentrations (14) . Also, simulation of a single ciprofloxacin dose (4) instead of conventional twice-daily dosing (the present study) may contribute to the above discrepancies. Despite the relatively high estimated anti-mutant AUC 24 /MIC ratio (average, 1,080 h; 720 to 1,440 h for the individual organisms), this ratio is attainable in a clinical setting. According to the AUCs reported in human pharmacokinetic studies with ciprofloxacin (500 mg twice a day), the AUC 24 of ϳ22 g·h/ml (15) is clinically achievable. Given this estimate, the clinically attainable AUC 24 /MIC ratio with E. coli strains 4300, 4454, and ATCC 25922 approaches 2,750 h and with E. coli GM2995 is 1,375 h, which is close to or larger than the anti-mutant AUC 24 /MIC ratio.
In conclusion, although AUC 24 /MPC as a strain-independent predictor of bacterial resistance did not exhibit any advantages over AUC 24 /MIC in the present study, the anti-mutant AUC 24 / MPC ratio established in the present study with E. coli (58 h) appeared to be close to the value reported in our study with fluoroquinolone (including ciprofloxacin)-exposed S. aureus (60 to 69 h [16] ) using the same in vitro model. Unlike AUC 24 /MPC, the anti-mutant AUC 24 /MICs for E. coli and S. aureus differ 5-fold: 1,080 h in the present study versus 200 to 240 h in the S. aureus study (16) . This implies that AUC 24 /MPC, but not AUC 24 /MIC, might be a species-independent predictor of bacterial resistance. Obviously, further studies with other organisms are needed to confirm this conclusion.
Overall, our findings support the MSW hypothesis, as applied to ciprofloxacin-exposed E. coli. However, continuing search for the optimal predictor(s) of mutant enrichment is encouraged.
